On the other hand, deleting UBE4A causes severe defects in animal models such as neuronal developmental defects[22], insulin resistance and hepatic steatosis [21], suggesting that UBE4A may not be a suitable treatment target for metabolic disease. Here, INS is linked to fatty liver disease.